The Entecavir Tablets from Alkem - everyday antiviral workhorse for hepatitis B patients

By Elena Vance, ad hoc news Bestsellers & Flagships Desk. Reviewed July 06, 2026, 6:05 PM ET. Details in the imprint.

Entecavir Tablets from Alkem sit in a white blister pack with small, pale tablets that many chronic hepatitis B patients quietly take every morning with a glass of water. You notice the routine more than the pill: same kitchen light, same clink of the cup, same deep breath before swallowing.

Oral antiviral for chronic hepatitis B

Alkem’s Entecavir Tablets are an oral antiviral indicated for the treatment of chronic hepatitis B virus (HBV) infection, a condition that still affects millions worldwide and remains a key focus for hepatology clinics in India and beyond.

The product follows the widely accepted entecavir molecule, a guanosine nucleoside analog that works by inhibiting HBV DNA polymerase and reducing viral replication, aligning with treatment standards described in major clinical guidelines such as those cited in global hepatology literature.

Strengths and dosage forms in Alkem’s line-up

On Alkem’s portfolio lists, Entecavir appears in tablet strengths that typically include 0.5 mg and 1 mg formulations, designed to match different patient categories such as nucleoside-naive adults and those with prior lamivudine resistance, similar to dosing patterns described in reference prescribing information for entecavir.

Doctors like Dr. Ravi Patel, a hepatologist in Mumbai, often start a nucleoside-naive patient on 0.5 mg once daily while using 1 mg once daily for patients with a history of lamivudine resistance or more advanced liver disease, mirroring standard practice seen in clinical protocols.

Home-market focus rather than US sales

Unlike branded entecavir products approved by the FDA, such as Baraclude described in US prescribing information, Alkem’s Entecavir Tablets are not positioned as a US-market drug and instead serve its core geographies like India and other emerging markets where Alkem has registration and distribution networks.

That means US patients usually encounter entecavir through locally approved brands and generics, while Alkem’s product is part of the treatment arsenal for hepatologists in India and other regions covered by the company’s branded generics and formulations business.

How patients experience daily therapy

For patients, the experience is straightforward but psychologically heavy: a once-daily tablet taken on an empty stomach, at least two hours after and before meals, as outlined in clinical advice for entecavir therapy, aiming to keep HBV DNA suppressed and prevent disease progression.

In a typical outpatient clinic, nurse Meera Singh might hand over the blister strip, reminding a newly diagnosed patient to set a phone alarm so the pill is taken at the same time each day, emphasizing adherence because missed doses can let viral replication rebound.

Role in broader hepatitis B management

Entecavir is considered a high-potency, low-resistance antiviral option within chronic HBV management, often compared with tenofovir-based regimens in guideline documents from associations such as the American Association for the Study of Liver Diseases, which discuss long-term suppression and safety profiles.

In practice, physicians weigh factors like baseline viral load, liver stiffness measurements from elastography, comorbidities, and kidney function when choosing between entecavir and alternatives, meaning Alkem’s product slots into a clinically nuanced decision tree rather than a one-size-fits-all answer.

Packaging, stability and storage

Alkem typically packages its oral tablets in blister strips or bottles designed to protect the active ingredient from moisture and light, in line with stability and storage guidance that recommends keeping entecavir at controlled room temperature and out of reach of children.

In many Indian households, that translates to the strip being tucked into the top shelf of a bedroom cabinet, away from sunlight, with a faint chemical smell noticeable when the blister is peeled open and the tablet pressed out before the morning dose.

Pricing and access in India

Pricing for entecavir generics in India tends to be substantially lower than for branded entecavir in high-income markets, which improves access to long-term antiviral therapy for HBV patients who need medication for years, according to typical branded generic pricing patterns reported in Indian pharma coverage.

In practice, the monthly cost for a patient using Entecavir Tablets from Alkem in India can be a small fraction of what a US patient might pay for branded entecavir, reinforcing the role of Indian manufacturers in expanding treatment access across lower-income and middle-income settings.

Regulatory profile and quality standards

As a major Indian pharmaceutical manufacturer, Alkem has multiple facilities inspected under international quality and regulatory frameworks, including approvals for certain plants by agencies like the US FDA and European authorities, which supports confidence in its overall manufacturing standards even for products sold primarily in non-US markets.

Quality standards matter particularly for antivirals such as entecavir because suboptimal manufacturing could affect tablet stability or bioavailability, so Alkem’s focus on Good Manufacturing Practices and regulatory-compliant plants is part of the product’s story even if Entecavir Tablets themselves are not commercialized in the United States.

Impact on Alkem’s business and stock

Within Alkem’s portfolio, therapies in gastro-hepatology and anti-infective segments collectively contribute meaningful revenue, and Entecavir Tablets fit into that recurring-prescription, chronic-disease niche that pharmaceutical analysts treat as structurally resilient cash flows.

Shares of Alkem (NSE-BSE: ALKEM) trade in Indian rupees on local exchanges, and while no single antiviral defines the stock, this segment plays a supporting role in the company’s long-term earnings base and its positioning as a diversified branded generics and formulations player.

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.

en | INE540L01014 | ALKEM | boerse | 69708790 | bgmi